Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

LAG3 expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

LAG3 elevation (1)

PD-L1 amplification + LAG3 overexpression (1)

LAG3 elevation (1)

PD-L1 amplification + LAG3 overexpression (1)

›

LAG3 expression	Melanoma	LAG3 expression	Melanoma	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
LAG3 expression	Melanoma	LAG3 expression	Melanoma	nivolumab/relatlimab-rmbw Sensitive: B - Late Trials nivolumab / relatlimab-rmbw Sensitive : B	nivolumab/relatlimab-rmbw Sensitive: B - Late Trials nivolumab / relatlimab-rmbw Sensitive : B
LAG3 expression	Gastric Cancer	LAG3 expression	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LAG3 expression	Renal Cell Carcinoma	LAG3 expression	Renal Cell Carcinoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
LAG3 expression	Nasopharyngeal Carcinoma	LAG3 expression	Nasopharyngeal Carcinoma	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
LAG3 expression	Squamous Cell Carcinoma of Head and Neck	LAG3 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3